

Rev03 DATASHEET

Update: Dec,14,2021

MCP-4/CCL13, Human

Cat. No.: Z02836

Product Introduction

Species	Human
Protein Construction	MCP-4 (Gln24-Thr98) Accession # Q99616
Purity	> 96% as analyzed by SDS-PAGE > 96% as analyzed by HPLC
Endotoxin Level	< 1 EU/µg of protein by LAL method
Biological Activity	Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human monocytes is in a concentration of 10.0-100.0 ng/ml.
Expression System	E. coli
Theoretical Molecular Weight	8.6 kDa
Formulation	Lyophilized from a 0.2 μm filtered solution in 20 mM PB, pH 7.4, 130 mM NaCl.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at 20°C. Avoid repeated freeze-thaw cycles.

Background

Target Background : CCL13 is a chemoattractant for monocytes and eosinophils, and activates basophils. In addition, it has been reported to be chemotactic for CD4⁺ and CD8⁺ T cells, with an activity almost equivalent to that of MCP-3. The bioactivities of CCL13 is most likely mediated by the CC chemokine receptors CCR-2 and CCR-3, both of which have been shown to bind CCL13.

Synonyms: SCYA13; MCP4; NCC-1; SCYL1; CKb10; CCL-13



For laboratory research use only. Direct human use, including taking orally and injection and clir orbidden.	nical use are